Spinal Stenosis Therapeutic Pipeline H1 2015 Review Research Report

DALLAS, March 11, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "Spinal Stenosis - Pipeline Review, H1 2015" therapeutic market research report provides an overview of the Spinal Stenosis's therapeutic pipeline.

The report Spinal Stenosis Pipeline Review, H1 2015 provides an overview of the Spinal Stenosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Spinal Stenosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Stenosis and special features on late-stage and discontinued projects. Complete report is available @ http://www.rnrmarketresearch.com/spinal-stenosis-pipeline-review-h1-2015-market-report.html .

Spinal stenosis is the narrowing of spaces in the spine (backbone) which causes pressure on the spinal cord and nerves. This disorder usually involves the narrowing of one or more of three areas of the spine. There are two types of spinal stenosis: lumbar stenosis and cervical stenosis. Acute and chronic neck and lower back pain represents a major health care problem in the United States. Spinal stenosis is part of the aging process, and predicting who will be affected is not possible. Spinal stenosis may result in low back pain as well as pain in the legs. Stenosis may pinch the nerves that control muscle power and sensation in the legs.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies discussed in this report include: LTT Bio-Pharma Co., Ltd., Mesoblast Limited, Sucampo Pharmaceuticals, Inc., Toray Industries, Inc., Yungjin Pharm Ind. Co., Ltd. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=310188 . (This is a premium report priced at US$2000 for a single user License.)

Drugs profile discussed in this report include: beraprost sodium SR, LT-0101, MPC-25Osteo, SPI-017, SPI-3608, YLS-1501.

Featured News & Press Releases:

• Dec 23, 2013: Sucampo Reports Results from Phase 2a Study of Intravenous Ion Channel Activator for Lumbar Spinal Stenosis
• Jan 11, 2013: Mesoblast's Neofuse Stem Cell Product Shows Positive Results In Phase II Lumbar Spinal Fusion Trial
• Jan 11, 2013: Mesoblast's Neofuse Stem Cell Product Shows Positive Results In Phase II Lumbar Spinal Fusion Trial

Global Markets Direct reports feature investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by an expert team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information.

Reasons to buy 

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Spinal Stenosis
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Spinal Stenosis pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore more reports of Central Nervous System (CNS) therapeutics Market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/central-nervous-system-cns-therapeutics .

About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel:  +1-888-391-5441
sales@rnrmarketresearch.com

Connect with Us: 

G+ / Google Plus: https://plus.google.com/u/0/104156468549256253075/

Twitter: https://twitter.com/RnRMR

Facebook: http://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed